Cardiovascular	cardiovascular	O	O	O	O
risk	risk	O	O	O	O
with	with	O	O	O	O
cyclooxygenase	cyclooxygenase	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
general	general	O	O	O	O
problem	problem	O	O	O	O
with	with	O	O	O	O
substance	substance	O	O	O	O
specific	specific	O	O	O	O
differences?Randomised	differences?randomised	O	O	O	O
clinical	clinical	O	O	O	O
trials	trials	O	O	O	O
and	and	O	O	O	O
observational	observational	O	O	O	O
studies	studies	O	O	O	O
have	have	O	O	O	O
shown	shown	O	O	O	O
an	an	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
,	,	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
,	,	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
and	and	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
during	during	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
cyclooxygenase	cyclooxygenase	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Adverse	adverse	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
effects	effects	O	O	O	O
occurred	occurred	O	O	O	O
mainly	mainly	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
exclusively	exclusively	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
concomitant	concomitant	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
.	.	O	O	O	O

Cyclooxygenase	cyclooxygenase	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
cause	cause	O	O	O	O
complex	complex	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
,	,	O	O	O	O
vascular	vascular	O	O	O	O
and	and	O	O	O	O
cardiac	cardiac	O	O	O	O
prostanoid	prostanoid	O	O	O	O
profiles	profiles	O	O	O	O
thereby	thereby	O	O	O	O
increasing	increasing	O	O	O	O
vascular	vascular	O	O	O	O
resistance	resistance	O	O	O	O
and	and	O	O	O	O
fluid	fluid	O	O	O	O
retention	retention	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
tends	tends	O	O	O	O
to	to	O	O	O	O
increase	increase	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
daily	daily	O	O	O	O
dose	dose	O	O	O	O
and	and	O	O	O	O
total	total	O	O	O	O
exposure	exposure	O	O	O	O
time	time	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
comparison	comparison	O	O	O	O
of	of	O	O	O	O
individual	individual	O	O	O	O
selective	selective	O	O	O	O
and	and	O	O	O	O
unselective	unselective	O	O	O	O
cyclooxygenase	cyclooxygenase	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
suggests	suggests	O	O	O	O
substance-specific	substance-specific	O	O	O	O
differences	differences	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
may	may	O	O	O	O
depend	depend	O	O	O	O
on	on	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
pharmacokinetic	pharmacokinetic	O	O	O	O
parameters	parameters	O	O	O	O
or	or	O	O	O	O
inhibitory	inhibitory	O	O	O	O
potency	potency	O	O	O	O
and	and	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
contributed	contributed	O	O	O	O
by	by	O	O	O	O
prostaglandin-independent	prostaglandin-independent	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

Diagnostic	diagnostic	O	O	O	O
markers	markers	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
N-terminal	n-terminal	O	O	O	O
pro	pro	O	O	O	O
brain	brain	O	O	O	O
natriuretic	natriuretic	O	O	O	O
peptide	peptide	O	O	O	O
(	(	O	O	O	O
NT-proBNP	nt-probnp	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
high-sensitive	high-sensitive	O	O	O	O
C-reactive	c-reactive	O	O	O	O
protein	protein	O	O	O	O
might	might	O	O	O	O
help	help	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
early	early	O	O	O	O
identification	identification	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
at	at	O	O	O	O
risk	risk	O	O	O	O
,	,	O	O	O	O
thus	thus	O	O	O	O
avoiding	avoiding	O	O	O	O
the	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
serious	serious	O	O	O	O
cardiovascular	cardiovascular	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

